{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-009399","form_type":"8-K","ticker":"BCDA","cik":"0000925741","company_name":"BioCardia, Inc.","filed_at":"2025-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.842034+00:00","generated_at":"2026-05-24T05:23:29.116833+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioCardia reports FY2024 net loss $7.9M, cash $2.4M; CardiAMP HF data to be presented at ACC March 30","bullets":["Net loss $7.9M vs $11.6M in 2023; net cash used in ops $8.0M vs $10.0M.","Revenue $58K vs $477K; R&D expense $4.4M (down from $7.7M); SG&A $3.7M (down from $4.4M).","CardiAMP HF trial results to be presented at ACC Late-Breaking Clinical Trials on March 30, 2025; data intended for FDA/PMDA registration.","Completed low-dose cohort of CardiALLO (BCDA-03); DSMB review Q2 2025. First commercial Morph DNA steerable introducers available.","Cash and cash equivalents $2.4M at year-end 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-009399","json":"https://secwatch.observer/filing/0001437749-25-009399.json","markdown":"https://secwatch.observer/filing/0001437749-25-009399.md","text":"https://secwatch.observer/filing/0001437749-25-009399.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/925741/000143774925009399/0001437749-25-009399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/925741/000143774925009399/bcda20250326_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T05:23:29.116833+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}